Extending patient treatment: Insights from the EINSTEIN-CHOICE trial
In this video (filmed in June 2018), Professor Jan Beyer Westendorf explores the considerations involved in the decision to extend anticoagulation beyond six months in patients who have suffered a venous thromboembolism (VTE), with a focus on the efficacy and safety outcomes from the EINSTEIN-CHOICE trial and how these translate into clinical practice.
This webinar was recorded in June 2018. This was a promotional webinar intended for UK Healthcare Professionals that was organised and fully funded by Bayer plc.
We are regularly updating our website with new resources to support you and your patients. Please click here to subscribe to receive electronic communications about Bayer’s products, services and events.
To access the latest version of the Xarelto 2.5mg, 10mg and 15/20 mg Summary of Product Characteristics (SmPC) as well as Xarelto Patient Information Leaflet (PIL), please click on the following link eMC Widget
Reporting adverse events and quality complaints
This medicine is subject to additional monitoring. This will allow quick identification of new safety information.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Bayer plc.
If you want to report an adverse event or quality complaint, reports can be directed to: Tel: 0118 206 3500 or Email: email@example.com
Further information is available on the "contact" tab at www.bayer.co.uk.